{"brief_title": "Efficacy and Safety of Oral Bosentan on Healing/Prevention of Digital (Finger) Ulcers in Patients With Scleroderma", "brief_summary": "In an earlier clinical trial, RAPIDS-1, conducted in scleroderma patients with or without digital ulcers at baseline, bosentan significantly reduced the number of new digital ulcers versus placebo. The purpose of the present trial (RAPIDS-2) is to evaluate the prevention and healing effects of bosentan versus placebo on digital ulcers over a 24-week treatment period.", "condition": "Systemic Sclerosis", "intervention_type": "Drug", "intervention_name": "Placebo", "description": "Oral tablets matching bosentan 62.5-mg tablets and bosentan 125-mg tablets", "arm_group_label": "Placebo", "other_name": "Ro 47-0203", "criteria": "Main Inclusion Criteria: - Systemic Sclerosis (SSc), diffuse or limited. - SSc patients with at least one digital ulcer at baseline qualifying as a cardinal ulcer. Main Exclusion Criteria: - Digital ulcers due to conditions other than SSc. - Severe pulmonary arterial hypertension (PAH) (Who class III and IV). - Malabsorption or any severe organ failure (e.g., lung, kidney, liver) or any life-threatening condition. - Treatment with parenteral prostanoids (prostaglandin E, epoprostenol, or prostacyclin analogs) during the past 3 months prior to randomization. - Treatment with inhaled or oral prostanoids one month prior to randomization. - Previous treatment with bosentan.", "gender": "All", "minimum_age": "18 Years", "maximum_age": "N/A", "healthy_volunteers": "No", "id": "NCT00077584.xml"}